Add-on perampanel in Lance-Adams syndrome
详细信息 查看全文
- 作者：Bernhard J. Steinhoff ; bsteinhoff@epilepsiezentrum.de" class="auth_mail" title="E-mail the corresponding author ; Matthias Bacher ; Christoph Kurth ; Anke M. Staack ; Reinhold Kornmeier
- 关键词：Perampanel ; Myoclonus ; Lance&ndash ; Adams syndrome ; Efficacy
- 刊名：Epilepsy & Behavior Case Reports
- 出版年：2016
- 出版时间：2016
- 年：2016
- 卷：6
- 期：Complete
- 页码：28-29
- 全文大小：194 K
文摘
Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic–clonic seizures. A positive effect was reported in some patients with epileptic myoclonic jerks in idiopathic generalized epilepsy and in progressive myoclonic epilepsy.
We treated a male patient with posthypoxic nonepileptic myoclonus (Lance–Adams syndrome) with add-on PER and achieved an almost complete cessation of jerks. This effect was reproducible and, therefore, we suggest that it might be worth trying PER in comparable cases.